检索结果-南通市图书馆

四川生理科学杂志 2022年第9期44卷 1686-1686页

作者： deepak l bhatt Brigham and Women's Hospital Heart and Vascular Center and Harvard Medical School Boston MA USA Piedmont Heart Institute Atlanta GA. USA New York Presbyterian Hospital Columbia University Medical Center and Cardiovascular Research Foundation New York NY USA Prairie Heart Institute Springfield IL USA Perelman School of Medicine University of Pennsylvania Philadelphia PA USA Miami Cardiac Vascular Institute Miami FL USA University of Alabama at Birmingham Birmingham AL USA Medtronic Santa Rosa CA USA University of Chicago Medicine Chicago IL USA

Background:The SYMPlICITY HTN-3(Renal Denervation in Patients With Uncontrolled Hypertension)trial showed the safety but not efficacy of the Symplicity system(Medtronic,Santa Rosa,CA,USA)at 6 months follow-up in patients with treatment-resistant *** final report presents the 36-month follow-up ***:SYMPlICITY HTN-3 was a single-blind,multicentre,sham-controlled,randomised clinical trial,done in 88 centres in the *** aged 18-80 years,with treatment-resistant hypertension on stable,maximally tolerated doses of three or more drugs including a diuretic,who had a seated office systolic blood pressure of 160 mm Hg or more and 24 h ambulatory systolic blood pressure of 135 mm Hg or more were randomly assigned(2:1)to receive renal artery denervation using the single electrode(Flex)catheter or a sham control.

关键词： hypertension drugs treatment

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

四川生理科学杂志 2020年第4期42卷 391-391页

作者： deepak l bhatt From Brigham and Women’s Hospital Heart and Vascular Center and Harvard Medical School Boston (D.L.B. C.P.C. B.M.S.) Colorado Prevention Center Clinical Research and Department of Medicine Division of Cardiovascular Medicine University of Colorado Anschutz Medical Campus Aurora (M.S.) the State University of New York Downstate School of Public Health Brooklyn (M.S.) the University of Michigan Ann Arbor (B.P.) li Ka Shing Knowledge Institute and the Division of Endocrinology and Metabolism St. Michael’s Hospital and the Departments of Medicine and Nutritional Sciences University of Toronto (L.A.L.) and the Division of Nephrology (D.Z.I.C.) and the Cardiovascular Division Department of Medicine Women’s College Hospital and Peter Munk Cardiac Centre (J.A.U.) University Health Network University of Toronto — all in Toronto the University of Texas Southwestern Medical Center and Parkland Health and Hospital System Dallas (D.K.M.) and Lexicon Pharmaceuticals The Woodlands (P.L.) — both in Texas Vanderbilt University Medical Center Nashville (J.B.L. J.P.D.) the Division of Endocrinology Diabetes and Clinical Nutrition Oregon Health and Science University Portland (M.C.R.) the Section of Endocrinology Yale School of Medicine New Haven CT (S.E.I.) Saint luke’s Mid America Heart Institute University of Missouri–Kansas City Kansas City (M.N.K.) the School of life and Health Sciences Aston University Birmingham (C.J.B.) and the Imperial Centre for Cardiovascular Disease Prevention Department of Primary Care and Public Health Imperial College London London (K.K.R.) — both in the United Kingdom the Department of Medicine Estudios Clínicos Latinoamérica Instituto Cardiovascular de Rosario Rosario Argentina (R.D.) Duke Clinical Research Institute Duke University School of Medicine Durham NC (R.D.L.) and Université de Paris French Alliance for Cardiovascular Trials Assistance Publique–Hôpitaux de Paris Hôpital Bichat INSERM Unité 1148 Paris (P.G.S.).

Background:The efficacy and safety of sodium-glucose cotransporter 2 inhibitors such as sotagliflozin in preventing cardiovascular events in patients with diabetes with chronic kidney disease with or without albuminur... 详细信息

关键词： Kidney cardiovascular Diabetes

Outcomes of Medicare beneficiaries hospitalised with transient ischaemic attack and stratification using the ABCD^(2) score

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Stroke & Vascular Neurology 2021年第2期6卷 314-318页

作者： Shreyansh Shah li liang Durgesh Bhandary Saga Johansson Eric E Smith deepak l bhatt Gregg C Fonarow Naeem D Khan Eric Peterson Janet Prvu Bettger Department of Neurology Duke University School of MedicineDurhamNorth CarolinaUSA Duke Clinical Research Institute DurhamNorth CarolinaUSA AstraZeneca UK ltd CambridgeUK Hotchkiss Brain Institute and Department of Clinical Neurosciences University of CalgaryCalgaryAlbertaCanada Division of Cardiology Brigham and Women's HospitalBostonMassachusettsUSA Division of Cardiology Ronald Reagan UCLA Medical CenterLos AngelesCaliforniaUSA

Background long-term outcomes for Medicare beneficiaries hospitalised with transient ischaemic attack(TIA)and role of ABCD^(2) score in identifying high-risk individuals are not *** We identified 40825 Medicare beneficiaries hospitalised from 2011 to 2014 for a TIA to a Get With The Guidelines(GWTG)-Stroke hospital and classified them using ABCD^(2)s of mortality and rehospitalisation(all-cause,ischaemic stroke,haemorrhagic stroke,myocardial infarction,and gastrointestinal and intracranial haemorrhage)for high-risk versus low-risk groups adjusted for patient and hospital *** Of the 40825 patients,35118(86%)were high risk(ABCD^(2)≥4)and 5707(14%)were low risk(ABCD^(2)=0-3).Overall rate of mortality during 1-year follow-up after hospital discharge for the index TIA was 11.7%,44.3% were rehospitalised for any reason and 3.6%were readmitted due to *** with ABCD^(2) score≥4 had higher mortality at 1 year than not(adjusted HR 1.18,95%CI 1.07 to 1.30).Adjusted risks for ischaemic stroke,all-cause readmission and mortality/all-cause readmission at 1 year were also significantly higher for patients with ABCD^(2) score≥4 vs *** contrast,haemorrhagic stroke,myocardial infarction,gastrointestinal bleeding and intracranial haemorrhage risk were not significantly different by ABCD^(2) *** This study validates the use of ABCD^(2) score for long-term risk assessment after TIA in patients aged 65 years and *** efforts for community-based follow-up care after TIA are needed for ongoing prevention in Medicare beneficiaries who were hospitalised for TIA.

关键词： admitted score prevention

Patterns of antidepressant therapy and clinical outcomes among ischaemic stroke survivors

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Stroke & Vascular Neurology 2021年第3期6卷 384-394,I0018-I0032页

作者： Mark R Etherton Shreyansh Shah Xu Haolin Ying Xian lesley Maisch Deidre Hannah Brianna lindholm Barbara lytle laine Thomas Eric E Smith Gregg C Fonarow lee H Schwamm deepak l bhatt Adrian F Hernandez Emily C O'Brien Neurology Massachusetts General HospitalBostonMassachusettsUSA Neurology Duke University School of MedicineDurhamNorth CarolinaUSA Duke Clinical Research Institute Duke UniversityDurhamNorth CarolinaUSA American Heart Association Inc DallasTexasUSA Clinical Neurosciences University of Calgary Cumming School of MedicineCalgaryAlbertaCanada Cardiology Ronald Reagan UCLA Medical CenterLos AngelesCaliforniaUSA Cardiovascular Medicine Brigham and Women's HospitalBostonMassachusettsUSA Cardiology Duke UniversityDurhamNorth CarolinaUSA Population Health Duke Clinical Research InstituteDurhamNorth CarolinaUSA

Background and purpose Depression is common after stroke and is often treated with antidepressant medications(AD).ADs have also been hypothesised to improve stroke recovery,although recent randomised trials were *** investigated the patterns of in-hospital AD initiation after ischaemic stroke and association with clinical and readmission *** All Medicare fee-for-service beneficiaries aged 65 or older hospitalised for ischaemic stroke in participating Get With The Guidelines-Stroke hospitals between April and December 2014 were eligible for this *** measures included days alive and not in a healthcare institution(home time),all-cause mortality and readmission within 1-year *** score(PS)-adjusted logistic regression models were used to evaluate the associations between AD use and each outcome *** also compared outcomes in patients prescribed selective serotonin reuptake inhibitors(SSRIs)AD versus those prescribed non-SSRI *** Of 21805 AD naive patients included in this analysis,1835(8.4%)were started on an AD at *** started on an AD had higher rates of depression and prior ischaemic stroke,presented with higher admission National Institutes of Health Stroke Scale score and were less likely to be discharged ***,patients started on an SSRI had lower rates of discharge to *** for stroke severity,patients started on an AD had worse all-cause mortality,all-cause readmission,major adverse cardiac events,readmission for depression and decreased ***,AD use was also associated with an increased risk for the sepsis,a falsification endpoint,suggesting the presence of residual *** Patients with ischaemic stroke initiated on AD therapy are at increased risk of poor clinical outcomes and readmission even after PS adjustment,suggesting that poststroke depression requiring medication is a poor prognostic *** research is needed to explore

关键词： prescribed admission founding

介入治疗还是非介入治疗——一个无需再争论的问题

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

美国医学会杂志（中文版） 2006年第6期25卷 370-372页

作者： deepak l. bhatt 刘芳（译）刘梅林（校） Cleveland Clinic Foundation Department of Cardiovascular Medicine Cleveland Ohio. 不详

不稳定心绞痛和非ST段抬高心肌梗死是急性冠脉综合征最常见的表现，也是患者人院的常见原因。尽管治疗方法已有进步，但是急性冠脉综合征的发生率和死亡率仍然居高不下。自上世纪90年代以来，心脏病学界一直在争论急性冠脉综合征早期介... 详细信息

不稳定心绞痛和非ST段抬高心肌梗死是急性冠脉综合征最常见的表现，也是患者人院的常见原因。尽管治疗方法已有进步，但是急性冠脉综合征的发生率和死亡率仍然居高不下。自上世纪90年代以来，心脏病学界一直在争论急性冠脉综合征早期介入处理是否优于“保守”处理。介入治疗意味着常规采用心导管检查确定治疗策略，而保守治疗则仅对反复发作的自发性或应激性心肌缺血患者进行导管检查。然而，介入治疗并非总能导致血运重建，而保守策略也不是彻底不需要导管检查。但在理论上，这两种处理手段仍被看成是对立的。

关键词：非介入治疗急性冠脉综合征心导管检查非ST段抬高不稳定心绞痛保守治疗心肌梗死治疗方法

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

血小板与心血管疾病

国外科技新书评介 2009年第5期 23-23页

作者： deepak l．bhatt

血小板在正常凝血、病理性出血和血栓症中具有关键作用，由血小板介导的动脉粥样硬化血栓形成性疾病是西方发达国家人群的主要死因之一。本书主要介绍了血小板在心血管疾病发生发展中的作用，抗凝血药物的作用机制及其在心血管疾病临床... 详细信息

血小板在正常凝血、病理性出血和血栓症中具有关键作用，由血小板介导的动脉粥样硬化血栓形成性疾病是西方发达国家人群的主要死因之一。本书主要介绍了血小板在心血管疾病发生发展中的作用，抗凝血药物的作用机制及其在心血管疾病临床治疗中的应用。

关键词：心血管疾病血小板西方发达国家动脉粥样硬化血栓形成临床治疗抗凝血病理性

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

普拉格雷临床价值分析

中国处方药 2009年第9期8卷 18-18页

作者： deepak l. bhatt 海燕

·对于非常可能实施PCI的急性冠脉综合征患者,普拉格雷治疗的效果较好,比如ST段抬高的心肌梗死患者,或者冠脉造影显示无ST段抬高的心肌梗死患者。·老年患者应避免使用,除非有高危因素。·低体重患者可选择低维持剂量,但还需要进一步证... 详细信息

·对于非常可能实施PCI的急性冠脉综合征患者,普拉格雷治疗的效果较好,比如ST段抬高的心肌梗死患者,或者冠脉造影显示无ST段抬高的心肌梗死患者。·老年患者应避免使用,除非有高危因素。·低体重患者可选择低维持剂量,但还需要进一步证实。·无ST段抬高的心肌梗死患者急诊常规选择普拉格雷还为时尚早。·急性冠脉综合征患者初始治疗选择普拉格雷的疗效还不明确,但已在研究之中。·复杂选择性PCI之后常规使用普拉格雷是有临床需求的,但在有进一步的证据之前还不宜使用。

关键词：价值分析急性冠脉综合征心肌梗死患者无ST段抬高临床造影显示 PCI

Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Signal Transduction and Targeted Therapy 2023年第11期8卷 5159-5183页

作者： Vivek Panwar Aishwarya Singh Manini bhatt Rajiv K.Tonk Shavkatjon Azizov Agha Saquib Raza Shinjinee Sengupta deepak Kumar Manoj Garg Department of Pharmaceutical Chemistry School of Pharmaceutical SciencesShoolini UniversitySolanHimachal Pradesh173229India Amity Institute of Molecular Medicine and Stem Cell Research(AIMMSCR) Amity University Uttar PradeshSector-125NoidaUttar Pradesh201313India Department of Biomedical Engineering Indian Institute of TechnologyRoparPunjab140001India Department of Pharmaceutical Chemistry School of Pharmaceutical SciencesDelhi Pharmaceutical Sciences and Research University(DPSRU)New Delhi110017India laboratory of Biological Active Macromolecular Systems Institute of Bioorganic ChemistryAcademy of Sciences UzbekistanTashkent100125Uzbekistan Faculty of life Sciences Pharmaceutical Technical University100084TashkentUzbekistan Rajive Gandhi Super Speciality Hospital TahirpurNew Delhi110093India

The mammalian target of rapamycin(mTOR)is a protein kinase that controls cellular metabolism,catabolism,immune responses,autophagy,survival,proliferation,and migration,to maintain cellular *** mTOR signaling cascade consists of two distinct multi-subunit complexes named mTOR complex 1/2(mTORC1/2).mTOR catalyzes the phosphorylation of several critical proteins like AKT,protein kinase C,insulin growth factor receptor(IGF-1R),4E binding protein 1(4E-BP1),ribosomal protein S6 kinase(S6K),transcription factor EB(TFEB),sterol-responsive element-binding proteins(SREBPs),lipin-1,and Unc-51-like autophagy-activating *** signaling plays a central role in regulating translation,lipid synthesis,nucleotide synthesis,biogenesis of lysosomes,nutrient sensing,and growth factor *** emerging pieces of evidence have revealed that the constitutive activation of the mTOR pathway due to mutations/amplification/deletion in either mTOR and its complexes(mTORC1 and mTORC2)or upstream targets is responsible for aging,neurological diseases,and human ***,we provide the detailed structure of mTOR,its complexes,and the comprehensive role of upstream regulators,as well as downstream effectors of mTOR signaling cascades in the metabolism,biogenesis of biomolecules,immune responses,and ***,we summarize the potential of long noncoding RNAs(lncRNAs)as an important modulator of mTOR ***,we have highlighted the potential of mTOR signaling in aging,neurological disorders,human cancers,cancer stem cells,and drug ***,we discuss the developments for the therapeutic targeting of mTOR signaling with improved anticancer efficacy for the benefit of cancer patients in clinics.

关键词： metabolism homeostasis mTOR

动脉粥样硬化血栓形成门诊患者1年内心血管事件的发生率

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

美国医学会杂志（中文版） 2007年第4期26卷 195-203页

作者： Gabriel Steg deepak l. bhatt Peter W. F. Wilson Ralph D＇ Agostino E. Magnus Ohman Joachim Roether Chiau-Suong liau Alan T. Hirsch Jean-louis Mas Yasuo Ikeda Michael J. Pencina Shinya Goto 徐成斌（译）李呈亿（校） Departement de Cardiologie Hopital Bichat-Claude Bernard Paris France Department of Cardiovascular Medicine Cleveland Clinic Cleveland Ohio Cardiology Division Emory University School of Medicine Atlanta Ga Statistics and Consulting Unit Department of Mathematics and Statistics Boston University Boston Mass Division of Cardiology Duke University Durham NC Department of Neurology Klinikum Minden Minden Germany Department of internal Medicine National Taiwan University Hospital and School of Medicine Taipei Taiwan Minneapolis Heart Institute Foundation and Division of Epidemiology and Community Health University of Minnesota School of Public Health Minneapolis Service de Neurologie Centre Raymond Garcin Hopital Sainte-Anne Paris France Department of Internal Medicine Keio University School of Medicine Tokyo Japan Department of Medicine Tokai University School of Medicine Kanagawa Japan 不详

背景：目前，有关社区中动脉粥样硬化血栓形成稳定患者心血管（cardiovascular，CV）事件发生率的资料比较少，既往也无国际性队列研究对冠状动脉病（coronary artery disease，CAD）、脑血管病（cerebrovascular disease，CVD）、外周... 详细信息

背景：目前，有关社区中动脉粥样硬化血栓形成稳定患者心血管（cardiovascular，CV）事件发生率的资料比较少，既往也无国际性队列研究对冠状动脉病（coronary artery disease，CAD）、脑血管病（cerebrovascular disease，CVD）、外周动脉病（peripheral arterial disease，PAD）确诊患者以及此类疾病高危患者不同事件的发生率进行评估。目的：在患有动脉疾病的门诊患者或存在多个动脉粥样硬化血栓形成危险因素的门诊患者中确定当今世界1年内CV事件的发生率。设计、地点及参试者：“减少动脉粥样硬化血栓形成维系健康（Reduction of Artherotllrombosis for Continued Health，REACH）”注册研究是一项国际前瞻性队列研究。研究人员于2003—2004年从44个国家、5587名医生入选68236例已确诊的动脉粥样硬化性血管病患者（CAD、PAD、CVD；n=55814）以及至少存在3个动脉粥样硬化血栓形成危险因素的患者（n=12422）。主要观测指标：CV死亡、心肌梗死（myocardial infarction，MI）及卒中的发生率。结果：截至2006年7月，共有95．22％的患者（n=64977）提供了1年内的结局。心血管死亡、MI及卒中的总体发生率为4．24％；动脉粥样硬化性血管病患者为4．69％，仅存在多个危险因素的患者为2．15％。CAD、CVD及PAD患者CV死亡、MI及卒中的总体发生率分别为4．52％、6．47％和5．35％。CAD、CVD及PAD患者发生终点事件（即CV死亡、MI、卒中）以及因动脉粥样硬化血栓形成事件入院的几率分别为15．20％、14．53％和21．14％。上述事件发生率随症状性动脉疾病病变部位数量的增加而增加，仅存在危险因素的患者为5．31％，有1处症状性动脉疾病的患者为12．58％，有2处症状性动脉疾病的患者为21．14％，有3处症状性动脉疾病的患者为26．27％（趋势P〈0．001）。结论：在这项当代大型国际研究中，患有动脉粥样硬化性血管病的门诊患者以及有动脉粥样硬化血栓形成危险的门诊患者CV事件的年发生率相对较高。存在多部位病变者CV事件的1年发生率升高。

关键词：动脉粥样硬化血栓形成心血管事件年发生率门诊患者动脉粥样硬化性血管病前瞻性队列研究 arterial 动脉疾病

Immunotherapy for recurrent hepatocellular carcinoma

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2023年第15期29卷 2261-2271页

作者： Ahan bhatt Jennifer Wu Division of Hematology and Oncology Perlmutter Cancer Center of NYU Langone HealthNYU School of MedicineNew YorkNY 10016United States

Hepatocellular carcinoma(HCC)is presented frequently in late stages that are not amenable for curative *** for patients who can undergo resection for curative treatment of HCC,up to 50%*** patients who were not exposed to systemic therapy prior to recurrence,recurrence frequently cannot be subjected to curative therapy or local *** patients have several options of immunotherapy(IO).This includes programmed cell death protein 1(PD-1)and cytotoxic T-lymphocyte associated protein 4 treatment,combination of PD-1 and vascular endothelial growth factor inhibitor or single agent PD-1 therapy when all other options are deemed *** are also investigational therapies in this area that explore either PD-1 and tyrosine kinase inhibitors or a novel agent in addition to PD-1 with vascular endothelial growth factor *** minireview explored IO options for patients with recurrent HCC who were not exposed to systemic therapy at the initial *** also discussed potential IO options for patients with recurrent HCC who were exposed to first-line therapy with curative intent at diagnosis.

关键词： liver neoplasms Immune checkpoint blockade Combination drug therapy PD-1-PD-l1 blockade CTlA-4 inhibitor